Kurin Works with The Ohio State University Wexner Medical Center on Patient Safety and Increased Access to High Quality Healthcare

/in ,

Kurin, Inc., a certified Minority Business Enterprise, and The Ohio State University Wexner Medical Center are working together to reduce contaminated blood cultures and improve high quality healthcare at Ohio State patient care centers.

“We are pleased to engage with this prestigious organization,” said Tom Thompson, Kurin Executive VP of Sales. “We are always impressed when hospitals demonstrate an unwavering commitment to their patients. We are similarly driven to improving patient outcomes and helping those who are providing care to these patients.”

This agreement:

  • Provides FDA 510(k)-cleared approaches to address contaminated blood culture problems.
  • Brings clinicians elegantly simple, intuitive technologies that help simplify clinical workflow, specimen stewardship, and prevention of sepsis misdiagnosis.

Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections. Kurin Lock® and Kurin Jet™ provide clinicians the tools they need to address these problems.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Final Judgment Entered in Kurin’s Favor over Magnolia Medical

/in ,

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that Chief Judge Connolly of the U.S. District Court for the District of Delaware entered Final Judgment that Kurin does not infringe Magnolia Medical, Inc.’s patent. The district court proceedings in the patent infringement lawsuit brought by Magnolia in 2019 are now closed.

“We are pleased that the Court has ruled in our favor,” said Bob Rogers, CEO of Kurin, Inc. “This case took five years and during that time Magnolia has loudly proclaimed that they would put Kurin out of business, creating confusion in the marketplace. We took the high road with our customers and, although it took years, we stayed true to our values and prevailed in the end.”

“Previously, on Dec. 1, 2023, the US Patent and Trademark Office issued a final rejection of the key patent claims that were the cornerstone of this litigation. This is a complete victory for our team, confirming both that the Kurin Lock does not infringe any Magnolia patent and that the asserted patent is invalid. We are pleased to have this distraction behind us and can now continue on our mission of partnering with clinicians to improve clinical and financial outcomes regarding blood culture contaminations.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections. Kurin Lock and Kurin Jet give clinicians the tools they need to address these problems.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin Announces Appointment of Chief Commercial Officer

/in ,

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced Christine Arme as their Chief Commercial Officer. Christine has been in the healthcare industry for 35 years, working in both start-up and scaled-growth stage healthcare organizations in both a domestic and international capacity. Most recently, Christine served as the Vice President of Healthcare Systems at Solventum (formerly 3M Healthcare), where she has been since 2015. She led the Key Account organization for the Medical Surgical business unit, which is the largest business group within Solventum.

“I am pleased to announce Christine’s arrival to Kurin,” said Bob Rogers, CEO of Kurin, Inc. “She has had a storied career, including being one of the key reasons for our success at Ivera Medical, the creators of the market-leading Curos Port Protector, which was acquired by 3M in 2015.”

“Her continuing success and evolving leadership roles have been a pleasure to watch and we are excited to have her return to our group. Kurin has had a very successful stretch, mirroring the performance of Ivera Medical. We are in a great position to accelerate this growth and Christine’s skill, leadership, and energy are exactly what we need to take Kurin to the next level.”

Christine is thrilled to be re-united with Ivera Medical leadership team and others and commented, “It’s like coming home to a familiar family that exudes a strong culture and a mission to improve healthcare, reduce costs, and help clinicians and patients – all of which I am very passionate about.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections. Kurin Lock and Kurin Jet give clinicians the tools they need to address these problems.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Court Determines that Kurin Does Not Infringe Magnolia Medical Patent

/in ,

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that Chief Judge Connolly of the U.S. District Court in Delaware issued an opinion in the patent litigation brought by Magnolia Medical, Inc. finding that “Kurin is entitled to a judgment of noninfringement of claims 1 and 24 of the #483 patent as a matter of law.”

“It is rewarding to receive the Court’s determination that Kurin does not infringe the ‘483 patent and I appreciate the efforts of our team over the last few years,” said Bob Rogers, CEO of Kurin, Inc. “From the beginning of this case, we felt confident that we would prevail and that the lawsuit was a desperate move by a competitor who could not compete in the marketplace.”

“Previously, on Dec. 1, 2023, the US Patent and Trademark Office issued a final rejection of these same two patent claims. This opinion by the Court confirms that even if these patent claims were valid, Kurin does not infringe them. With Magnolia’s case now largely behind us, we can continue to focus on helping hospitals improve clinical outcomes and address the financial challenges posed by blood culture contamination.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections. Kurin Lock and Kurin Jet give clinicians the tools they need to address these problems.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Reports Record Revenue for Q1 2024

/in ,

Kurin, Inc., the inventor and manufacturer of Kurin® blood culture collection sets announced record revenues for the first quarter of 2024, following a record 2023. Despite a challenging healthcare environment, revenue in Q1 was ~30% higher than Q1 2023 and ~8% higher than Q4 2023, which was also a record quarter for Kurin.

“We are pleased with Kurin’s continued success and rate of market adoption, and I am grateful for the professionalism and dedication of our team,” said Bob Rogers, CEO of Kurin, Inc. “We continue our expansion of the sales, clinical and manufacturing teams to meet future growth requirements, leaving us well positioned for the changes CMS is forecasting in the blood culture contamination market.”

“We remain the market leader due to our small, simple device, and our continual quest to develop improvements to the Kurin Lock family,” said Rogers. “Hospitals are facing critical financial pressures and Kurin helps those facilities improve their quality of care, and reduce costs at the same time.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections. Kurin Lock and Kurin Jet give clinicians the tools they need to address these problems.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Files False Advertising Lawsuit Against ICU Medical and Vascular Integrity

/in ,

Kurin, Inc. announced that it filed a lawsuit against ICU Medical, Inc. and Vascular Integrity, LLC for making false and misleading clinical performance claims regarding the Vascular Integrity Bypass Syringe. The lawsuit was filed on March 15, 2024, in the US District Court, Central District of California. The syringe is manufactured by Vascular Integrity and ICU Medical is the distributor of this product.

“Kurin is the market leader in the blood culture contamination device market and our success is no doubt observed by others wondering how they might take advantage of the interest we have generated,” said Bob Rogers, Inventor and CEO of Kurin. “In this case, misleading claims that the Bypass Syringe reduces blood culture contamination, CLABSIs, and hemolysis are not supported in the regulatory documents. These statements are not only misleading, hospitals believing these claims could actually cause patient harm.”

“We filed this suit because Defendants ignored our friendly notice of these unsupported claims. Given their inattention to this matter, litigation was our only avenue to address these misleading statements.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections. Kurin Lock and Kurin Jet give clinicians the tools they need to address these problems.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

USPTO Examiner Affirms Rejection of Claims Asserted by Magnolia Medical, Inc. against Kurin, Inc.

/in ,

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that the US Patent and Trademark Office has issued a Reexamination Advisory Action regarding the relevant claims of the ‘483 patent that Magnolia Medical asserted against the Kurin Lock product. The Patent Office found that Magnolia’s arguments regarding claims 1 and 24 do not overcome its prior final rejection of these claims, and noted that any finally rejected claims will be cancelled.

“We are pleased to see yet another affirmation that we are on the right side of this legal process,” said Bob Rogers, CEO of Kurin, Inc. “The Advisory Action is unambiguous and offers great detail on why the arguments presented by Magnolia fail to overcome the USPTO’s determination that these claims are not valid, providing great clarity on this legal matter.”

“Magnolia Medical continues to abuse the legal system and the patent continuation process in an attempt to use the Courts and USPTO to do what it cannot do in the marketplace. We will continue to vigorously defend our rights. Kurin is the market leader in this space due to the ease-of-use of the Kurin product line, and continues to grow at a fast pace with further innovations being developed.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections. Kurin Lock and Kurin Jet give clinicians the tools they need to address these problems.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

USPTO Issues Final Rejection of Magnolia Medical’s ‘483 Patent at Issue in Litigation

/in ,

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced today that the US Patent and Trademark Office has issued a Final Rejection in its reexamination of claims 1 and 24 of U.S. Patent No. 10,039,483 (the ‘483 patent). Claims 1 and 24 of the ‘483 patent were asserted by Magnolia Medical against Kurin’s Lock product in a patent infringement case in Delaware Federal Court. The USPTO Examiner has rejected Magnolia’s arguments regarding patentability, and the pertinent claims of that patent now stand as rejected.

“We are pleased that the Examiner has rejected the asserted claims of the ‘483 patent,” said Bob Rogers, Inventor and CEO of Kurin, Inc. “Magnolia has tried to use this patent and subsequent litigation to create confusion in the marketplace and this action by the USPTO provides greater clarity to Kurin and other interested parties. As we have said from the onset, although this legal process is long, we are confident in our position, and will do whatever is necessary to continue to provide the market-leading Kurin family of products to our customers.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections. Kurin Lock and Kurin Jet give clinicians the tools they need to address these problems.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Reports Record Revenue for Q3 2023

/in ,

Kurin, Inc., the inventor and manufacturer of Kurin® blood culture collection sets announced record revenues for the third quarter of 2023. In spite of 2023’s economic challenges for hospitals and other adverse market conditions, revenue growth in Q3 was significantly higher than Q2 of this year and when compared to the same period last year.

“We are pleased with Kurin’s continuing success, as demonstrated by the impressive growth this past quarter,” said Bob Rogers, CEO of Kurin, Inc. “Although pioneering new technologies has its challenges, we are helped by delivering a combination of improved clinical outcomes without creating extra work, and our value proposition of saving hospitals significant money in the process.”

“We continue to build our organization to accommodate this growth and are preparing for the acceleration that is expected given the focus organizations like the CDC and CMS are giving blood culture contaminations,” said Mr. Rogers. “In addition to our ongoing hiring of quality professionals, we are examining expanded manufacturing options as we plan for future growth.”

Kurin’s revolutionary approach to the contaminated blood culture problem is based on elegantly simple, intuitive designs that require no additional user steps. Kurin Lock® and Kurin Jet™ both sideline potential contaminants during blood culture collection and provide a better and more sustainable approach than active, conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays, and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections. Kurin Lock and Kurin Jet give clinicians the tools they need to address these problems.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Named 2023 Diverse Supplier of the Year by Vizient

/in ,

Kurin, Inc. has been named the 2023 Diverse Supplier of the Year by Vizient, Inc., the nation’s largest provider-driven healthcare performance improvement company. The recognition was celebrated Sept. 18-21 at the 2023 Vizient Connections Summit in Las Vegas.

The Diverse Supplier of the Year award recognizes a certified minority-, woman-, veteran-, LGBT-, or disabled-person-owned supplier who has performed at the highest level in demonstrating year-over-year growth within Vizient-contracted customer spend while maintaining responsiveness to customer needs. This year, Vizient recognized Kurin for excelling in philanthropy, sustainability, performance in ethics and integrity, participation in Vizient events, and adherence to reporting and payment requirements.

“We are pleased to receive this award from Vizient,” said Bob Rogers, Inventor and CEO of Kurin. “From the time we started this company, our goal has been to make a difference by improving clinical outcomes and helping hospitals financially, as well as being good citizens along the way. We work with many Vizient member hospitals in these shared goals and look forward to continuing to do so for many years.”

“We are pleased to recognize Kurin as this year’s Diverse Supplier of the Year. Kurin has delivered on our provider customers’ needs to optimize cost, quality, and market performance,” said Simrit Sandhu, executive vice president, clinical supply solutions, Vizient.

Kurin’s revolutionary approach to the contaminated blood culture problem is based on elegantly simple, intuitive designs that require no additional user steps. Kurin Lock® and Kurin Jet™ both sideline potential contaminants during blood culture collection and provide a better and more sustainable approach than active, conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays, and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections. Kurin Lock and Kurin Jet give clinicians the tools they need to address these problems.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.